PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Gregory G. Schwartz Articles

What have PCSK9 mAb trials taught us about lipoprotein(a)?

What have PCSK9 mAb trials taught us about lipoprotein(a)?

Reports from the 23rd Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Gregory G. Schwartz Supporters of the 23rd Scientific Expert Meeting of the Editorial Board AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or…

read more »
Posted on 22 October 2025 | Posted by Gregory G. Schwartz | Posted in 23rd Closed Scientific Expert Meeting of the Editorial Board
ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)

ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)

Reports from the 9th Closed Expert Meeting of the PCSK9 Education and Research Forum Gregory Schwartz and Michael Szarek 

read more »
Posted on 11 December 2018 | Posted by Gregory G. Schwartz, Michael Szarek | Posted in Webcasts, 9th Closed Scientific Expert Meeting of the Editorial Board
Profiling patients with ACS: What are the prospects for PCSK9 inhibition?

Profiling patients with ACS: What are the prospects for PCSK9 inhibition?

Reports from the 7th Expert Meeting of PCSK9 Forum Gregory G. Schwartz, VA Medical Center and University of Colorado School of Medicine, Denver

read more »
Posted on 18 October 2017 | Posted by Gregory G. Schwartz | Posted in Webcasts, 7th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.

LIB Therapeutics

Novartis

Sanofi

© Copyright 2026 PCSK9 Forum. All rights reserved